Lily pollen was developed to express HBsAg by Agrobacterium-mediated transformation. A double prime-boost strategy combining parenteral and oral HBsAg boosters was found to increase antibody titer levels 10-fold, as compared to a single process of priming and boosting. Lily pollen may prove a tool for oral vaccine development.
Lily pollen was developed to express HBsAg by Agrobacterium-mediated transformation. A double prime-boost strategy combining parenteral and oral HBsAg boosters was found to increase antibody titer levels 10-fold, as compared to a single process of priming and boosting. Lily pollen may prove a tool for oral vaccine development.
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Although a safe and effective hepatitis B vaccine is readily available in many countries, it is less accessible in poorer countries due to its cost. As an alternative, a plantbased oral vaccine has been developed that has advantages such as simple administration and cost-effectiveness.
1) The antigens encapsulated in plant cells are known to be protected from gastric digestion until they are released in the intestines, where they come in contact with Peyer's patches and induce immune responses. 2) Potatoes expressing HBsAg have been verified as to oral immunogenicity in mice and humans. 3, 4) Lily pollen, which is abundantly available from cultivated lily plants, is a convenient tool for studying pollen germination, tube growth, and gene expression.
5)
The advantages of using transgenic lily pollen include easy access to it, viability for long years under freezing conditions, and rapid and simple in vitro cultivation. In this study, we introduced the HBsAg gene into lily pollen by Agrobacterium-mediated transformation and evaluated the oral immunogenicity of HBsAg-expressing lily pollen in mice.
Cut lily plants (Lilium longiflorum cv. Georgia) in the inflorescence stage were obtained from local flower market. Pollen grains were collected by tapping dehisced lily anthers on a steel sieve (40 mesh size), and were stored at À70 C. Pollen growth was carried out in the dark for 24 h at 27 C in liquid pollen germination medium (PGM) containing 10% (w/v) sucrose, 1.6 mM H 3 BO 3 , and 1.8 mM Ca(NO 3 ) 2 , pH 5.7.
6)
The HBsAg coding regions were amplified by PCR from pAM6 (ATCC 40101) with HBsAg-specific primers (forward, 5 0 -acggatcccgggtcaacgaacatggagaacatcacatca-3 0 ; reverse, 5 0 -ccggagctctagggtttaaatgtatacccaaagac-3 0 ). The PCR products were cloned as BamH I/ Sac I fragments into pBI121ÁGUS to yield expression vector pBI-HBsAg under the control of the CaMV35S promoter. Agrobacterium-mediated transformation was carried out by infiltrating pollen grains with A. tumefaciens LBA4404 cells harboring pBI-HBsAg. To this end, 300 mg of pollen grains was vigorously shaken for 3 min in the presence of 900 mg of aluminum oxide particles (size, average 40-100 mm), suspended in 50 mL PGM, vacuum-infiltrated for 10 min with 100 mL of Agrobacterium cells grown overnight in LB medium with 50 mg/mL of kanamycin to OD 600 ¼ 1:2 and then incubated for 24 h. 6) To verify DNA transfer, lily pollen cultures were collected with a sieve and surface sterilized with 70% ethanol (1 min), followed by 2% sodium hypochlorite (2 min) and washed thoroughly with distilled water. No bacterial colonies were observed after this sterilization step. Also, no bacterial colonies developed from the homogenized pollen culture. Genomic DNA was isolated by the CTAB method 7) after powdering the pollen culture in LN 2 , digested with BamH I and EcoR I, resolved by 1% agarose gel electrophoresis, and blotted on a NytranÔ nylon membrane. Hybridization and detection were done according to the protocol provided by the Bright-Star detection system (Ambion, Boston, MA). The probe DNA consisting of 0.7 kb-DNA fragments generated by digestion of pBI-HBsAg with BamH I and Sac I was labeled with a Bright-StarÔ Psoralen-biotin nonradioisotopic labeling kit (Ambion, Boston, MA). To detect HBsAg protein expression, pollen culture extracts were resolved by 12% polyacrylamide gel electrophoresis, blotted on a PVDF membrane, reacted with a monoclonal antibody against HBsAg antigen, and detected by the ECL Western blotting detection system (Amersham, Piscataway, NJ). The pollen cultures, ground in LN 2 , were dissolved in PBS and centrifuged at 12,000 rpm for 10 min to obtain the supernatant, in which the concentration of HBsAg was measured with an AxSYM HBsAg (V2) kit in an IMx detector (Abbott, Abbott Park, IL).
BALB/c mice were fasted overnight and then fed cultivated pollen. Non-transformed pollen culture was used as control. In each experiment, 10 mice were administered 50 mg of pollen culture/kg of body weight by intra-gastric intubation 2 times per week following the immunization protocol (Figs. 2 and 3) . The mice were injected with a sub-immunogenic dose (0.5 mg of yeast-derived rHBsAg) of commercial vaccine (Green Cross, Seoul, Korea) as primer or booster by the intramuscular route. Anti-HBsAg antibodies from mouse serum were titrated by AUSAB EIA in an IMx detector (Abbott, Abbott Park, IL). The AUSAB standard panel was included with each assay performed, which permitted the conversion of OD values to mIU/mL.
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Note
The HBsAg gene, which encodes the small surface antigen of an Adw HBV isolate, was subcloned into pBIHBsAg binary vector (Fig. 1A) . We introduced pBIHBsAg into the lily pollen and then analyzed its T-DNA integration. Southern blot hybridization was carried out for two individual transformation experiments. As shown in Fig. 1B , the HBsAg gene was successfully introduced in both transformations, but not in the nontransformed materials. Western blotting was used to investigate the accumulation of HBsAg protein in the transgenic pollen. The signal band was compared against yeast rHBsAg as positive control (Fig. 1C) . Two independent transgenic pollen cultures showed bands of identical density. Some bands that were positioned lower than the band of rHBsAg were assumed to be degraded products. The concentration of HBsAg was determined to be 89 ng/g of fresh pollen culture, a concentration similar to or lower than the expression levels reported for other transgenic plant studies. 4, 8) The immunogenicity of the transgenic pollen was tested by orally immunizing mice with HBsAg-expressing lily pollen cultures. Retro-orbital bleeding was used to assess for the presence of specific antibodies. Within 4 weeks, we could not detect primary antibodies after oral administration of transgenic pollen alone. Similar results were obtained in previous studies using transgenic potatoes and cherry tomatillos. 8, 9) In the present study, the mice were injected with a sub-immunogenic dose (0.5 mg of HBsAg) of commercial vaccine, and then boosted with transgenic pollen for various periods of time. After a single injection for priming, their antibody titers sharply increased, to 79 AE 46 mIU/mL, in response to the antigen, and then declined. Within several weeks, the mice boosted with the transgenic pollen developed serum antibody concentrations of 261 AE 125, 294 AE 136, and 261 AE 148 mIU/mL after they were boosted 8, 18, and 28 times respectively for 4 to 8 weeks. No significant increase in antibody titers was detected due to more than 18 pollen vaccinations (Fig. 2) . It was evident that oral booster immunizations significantly augmented the antibody titer levels in the serum. The mice fed wild-type pollen cultures did not show any booster response. We concluded that a recall response elicited by pollen-derived HBsAg was successfully established following parenteral priming. Further Mice were administered HBsAg pollen or vehicle for pollen dissolution (distilled water) 2 times a week for 4 weeks 1 week following commercial vaccine priming. After a 2-week resting period, they were administered the pollens described above 5 times a week for 4 weeks. Values represent mean AE SEM for 10 mice per group. The HBsAg antibody titers of the mice administered HBsAg pollen were significantly higher (p < 0:05) than those of the control mice (prime only). immunization was achieved by means of an additional booster with commercial vaccine and subsequent pollen immunization for 4 weeks after the first primer and booster. The antibody titer levels in serum were measured to be 5760 AE 2962 mIU/mL, in comparison to 535 AE 293 mIU/mL from the first primer and booster (Fig. 3) . This 10-fold increase in antibody titer was remarkable, and indicates that transgenic pollen is an excellent immuno-booster effector in combination with a primer and booster injection of the commercial vaccine. The levels of specific antibodies significantly exceeded the protective level of 100 mIU/mL in humans. 10) Transient HBsAg expression in lily pollen was confirmed after Agrobacterium-mediated transformation. It was found that oral administration of HBsAg lily pollen to the mice significantly elevated their serum anti-HBsAg antibody titer levels.
Vaccination in the following delivery order is recommended: parenteral, oral, parenteral, and oral. The proper combination of parenteral and oral delivery might eventually yield the most successful immune response. Humoral anti-HBsAg responses to orallyadministered HBsAg were nevertheless detected. This might have been due to low doses of antigen delivered to the immune effector locus and/or antigens interfering with the pollen material and not properly evoking an immune response.
Lily pollen is not commonly eaten, but its safety as an edible can be assured through good laboratory practice. 11) In this context, the lily pollen-based system might be proposed as a potential edible vaccine vector for direct and rapid application.
